Therapeutic pathomorphism of transitional cancer due to intravesical prospidin and cisplatin chemotherapy in patients with non-muscle-invasive bladder cancer
Автор: Selivanov S.P., Yalоvа М.F., Shаbunina Т.I., Isaeva S.N., Kovalik Т.А., Реtlin А.V.
Журнал: Сибирский журнал клинической и экспериментальной медицины @cardiotomsk
Рубрика: В помощь практическому врачу
Статья в выпуске: 4-2 т.25, 2010 года.
Бесплатный доступ
Proliferative activity of transitional cancer was studied. Patients with non-muscle invasive bladder cancer have intravesical chemotherapy as a presurgery treatment. Prospidin was instillated in a single dose 200 mg to total dose 4000 mg, cisplatin - in 20 mg and 500 mg, respectively. Both prospidin and cisplatin reduce proliferative activity and demonstrate similar therapeutic pathomorphism.
Non-muscle-invasive bladder cancer, neoadjuvant intravesical chemotherapy, prospidin, cisplatin
Короткий адрес: https://sciup.org/14920241
IDR: 14920241
